SG11202100026WA - P2x3 receptor antagonists - Google Patents
P2x3 receptor antagonistsInfo
- Publication number
- SG11202100026WA SG11202100026WA SG11202100026WA SG11202100026WA SG11202100026WA SG 11202100026W A SG11202100026W A SG 11202100026WA SG 11202100026W A SG11202100026W A SG 11202100026WA SG 11202100026W A SG11202100026W A SG 11202100026WA SG 11202100026W A SG11202100026W A SG 11202100026WA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor antagonists
- antagonists
- receptor
- Prior art date
Links
- 102100040460 P2X purinoceptor 3 Human genes 0.000 title 1
- 101710189970 P2X purinoceptor 3 Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1811452.0A GB2575490A (en) | 2018-07-12 | 2018-07-12 | P2X3 receptor antagonists |
| PCT/EP2019/068681 WO2020011921A1 (en) | 2018-07-12 | 2019-07-11 | P2x3 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100026WA true SG11202100026WA (en) | 2021-01-28 |
Family
ID=63273324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100026WA SG11202100026WA (en) | 2018-07-12 | 2019-07-11 | P2x3 receptor antagonists |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11999732B2 (en) |
| EP (1) | EP3820566A1 (en) |
| JP (1) | JP7418396B2 (en) |
| KR (1) | KR20210031925A (en) |
| CN (1) | CN112584898B (en) |
| AU (1) | AU2019300335A1 (en) |
| BR (1) | BR112021000103A2 (en) |
| CA (1) | CA3106131A1 (en) |
| EA (1) | EA202190215A1 (en) |
| GB (1) | GB2575490A (en) |
| IL (1) | IL279960B2 (en) |
| MX (1) | MX2021000408A (en) |
| SG (1) | SG11202100026WA (en) |
| WO (1) | WO2020011921A1 (en) |
| ZA (1) | ZA202007980B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112778311B (en) * | 2019-11-01 | 2024-06-04 | 上海翰森生物医药科技有限公司 | Nitrogen-containing fused ring derivative inhibitor, preparation method and application thereof |
| WO2022175514A1 (en) | 2021-02-22 | 2022-08-25 | Bayer Aktiengesellschaft | N-(pyridin-2-yl)-acetamides as p2x3 inhibitors |
| CN114516826A (en) * | 2022-02-21 | 2022-05-20 | 八叶草健康产业研究院(厦门)有限公司 | Preparation method of melatonin |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3982000A (en) * | 1973-01-19 | 1976-09-21 | Sandoz, Inc. | Alkyl-substituted-tricyclic quinazolinones as bronchodilators |
| DE3046366A1 (en) * | 1980-12-09 | 1982-07-08 | Bayer Ag, 5090 Leverkusen | TRICYCLIC CYTOSINE DERIVATIVES FOR USE IN MEDICINAL PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF |
| DE3146599A1 (en) * | 1981-11-25 | 1983-07-07 | Basf Ag, 6700 Ludwigshafen | NEW TRIAZOLOCHINAZOLINES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
| US4713383A (en) * | 1984-10-01 | 1987-12-15 | Ciba-Geigy Corporation | Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses |
| EP0181282A1 (en) * | 1984-10-01 | 1986-05-14 | Ciba-Geigy Ag | Triazoloquinazoline compounds |
| EP0263071B1 (en) * | 1986-09-30 | 1992-08-12 | Ciba-Geigy Ag | 2-Substituted-e-fused-[1,2,4]-triazolo[1,5-c] pyrimidines, pharmaceutical compositions, and uses thereof |
| US5212310A (en) * | 1991-12-19 | 1993-05-18 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
| US5792766A (en) * | 1996-03-13 | 1998-08-11 | Neurogen Corporation | Imidazo 1,5-c! quinazolines; a new class of GABA brain receptor ligands |
| US6013650A (en) * | 1996-03-14 | 2000-01-11 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
| IT1303272B1 (en) * | 1998-10-29 | 2000-11-06 | Zambon Spa | TRICYCLIC DERIVATIVES INHIBITORS OF PHOSPHODIESTERASE 4 |
| GB9824897D0 (en) | 1998-11-12 | 1999-01-06 | Merck Sharp & Dohme | Therapeutic compounds |
| JP2001160488A (en) * | 1999-12-01 | 2001-06-12 | Konica Corp | Organic electroluminescent element |
| CA2413330A1 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
| EP1471066A1 (en) | 2003-04-24 | 2004-10-27 | Aventis Pharma Deutschland GmbH | Triaza- and tetraaza-anthracenedione derivates, their preparation and their use as pharmaceuticals |
| EP1719756A4 (en) | 2004-02-18 | 2007-09-26 | Banyu Pharma Co Ltd | Nitrogenous fused heteroaromatic ring derivative |
| JP5718332B2 (en) * | 2009-08-06 | 2015-05-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Novel bicyclic urea compounds |
| JP5423363B2 (en) | 2009-12-07 | 2014-02-19 | コニカミノルタ株式会社 | Organic electroluminescence element, display device and lighting device |
| ES2687693T3 (en) * | 2011-09-30 | 2018-10-26 | C&C Research Laboratories | New heterocyclic derivatives and their uses |
| WO2013192225A1 (en) | 2012-06-18 | 2013-12-27 | Dart Neuroscience (Cayman) Ltd | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
| GB201406486D0 (en) * | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
| US20160083400A1 (en) * | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| WO2017046603A1 (en) * | 2015-09-18 | 2017-03-23 | Redx Pharma Plc | Antibacterial compounds and new uses thereof |
| CN108178759B (en) * | 2018-01-05 | 2020-06-09 | 上海瑞纷医药科技有限责任公司 | Synthesis method of α -adrenoceptor antagonist |
-
2018
- 2018-07-12 GB GB1811452.0A patent/GB2575490A/en not_active Withdrawn
-
2019
- 2019-07-11 AU AU2019300335A patent/AU2019300335A1/en active Pending
- 2019-07-11 WO PCT/EP2019/068681 patent/WO2020011921A1/en unknown
- 2019-07-11 BR BR112021000103-4A patent/BR112021000103A2/en unknown
- 2019-07-11 CN CN201980046603.6A patent/CN112584898B/en active Active
- 2019-07-11 CA CA3106131A patent/CA3106131A1/en active Pending
- 2019-07-11 IL IL279960A patent/IL279960B2/en unknown
- 2019-07-11 EA EA202190215A patent/EA202190215A1/en unknown
- 2019-07-11 US US17/259,511 patent/US11999732B2/en active Active
- 2019-07-11 MX MX2021000408A patent/MX2021000408A/en unknown
- 2019-07-11 EP EP19748719.2A patent/EP3820566A1/en active Pending
- 2019-07-11 SG SG11202100026WA patent/SG11202100026WA/en unknown
- 2019-07-11 KR KR1020217003658A patent/KR20210031925A/en not_active Application Discontinuation
- 2019-07-11 JP JP2021500684A patent/JP7418396B2/en active Active
-
2020
- 2020-12-21 ZA ZA2020/07980A patent/ZA202007980B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202007980B (en) | 2022-01-26 |
| GB2575490A (en) | 2020-01-15 |
| JP7418396B2 (en) | 2024-01-19 |
| BR112021000103A2 (en) | 2021-03-30 |
| CA3106131A1 (en) | 2020-01-16 |
| GB201811452D0 (en) | 2018-08-29 |
| US20210246139A1 (en) | 2021-08-12 |
| EA202190215A1 (en) | 2021-04-15 |
| US11999732B2 (en) | 2024-06-04 |
| IL279960B1 (en) | 2023-11-01 |
| IL279960B2 (en) | 2024-03-01 |
| MX2021000408A (en) | 2021-05-31 |
| EP3820566A1 (en) | 2021-05-19 |
| CN112584898B (en) | 2024-01-26 |
| AU2019300335A1 (en) | 2021-01-28 |
| JP2021524492A (en) | 2021-09-13 |
| WO2020011921A1 (en) | 2020-01-16 |
| KR20210031925A (en) | 2021-03-23 |
| CN112584898A (en) | 2021-03-30 |
| IL279960A (en) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274883A (en) | Novel bradykinin b2 receptor antagonists | |
| IL258892B (en) | Cgrp receptor antagonists | |
| IL279960A (en) | P2x3 receptor antagonists | |
| IL270971A (en) | Anti-igf-i receptor antibody | |
| GB201905552D0 (en) | Antagonists | |
| HK1249095A1 (en) | Cgrp receptor antagonists | |
| IL258894A (en) | Cgrp receptor antagonists | |
| GB201702617D0 (en) | Receptor | |
| GB201911187D0 (en) | Receptor | |
| IL258893A (en) | Cgrp receptor antagonists | |
| GB201801831D0 (en) | Chimeric receptor | |
| GB201815629D0 (en) | Antagonists | |
| GB201816639D0 (en) | GLP-1 Receptor Antagonist | |
| EP4069708A4 (en) | Sstr5 antagonists | |
| IL283413A (en) | Antagonists | |
| GB201816650D0 (en) | GLP-1 Receptor antagonists | |
| GB201707499D0 (en) | Orexin receptor antagonists | |
| GB201707504D0 (en) | Orexin receptor antagonists | |
| GB201702174D0 (en) | Orexin receptor antagonists | |
| GB201701887D0 (en) | Receptor | |
| GB201700926D0 (en) | Receptor |